HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd.

This corresponds to a highly significant alteration in HER3 expression ( p < 0.001 for marginal homogeneity) with an up‐regulation of HER3 expression from baseline to surgery in 6/58 (10.3%; 95% CI, 4.8% to 20.8%), and a decrease in response to NET in 23/58 cases (39.7%; 95% CI, 28.1 to 52.5%, Supplementary Table S5 ).

also in 132,142 other papers